Drug Profile
Research programme: vascular targeting agents - AGC Biologics
Alternative Names: NGR-IFN gamma; NGR-IFNγ; NGR-IL12Latest Information Update: 29 Oct 2020
Price :
$50
*
At a glance
- Originator MolMed
- Class Recombinant fusion proteins
- Mechanism of Action Capillary permeability modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 30 Sep 2020 MolMed has been acquired by AGC Biologics and changed its name to AGC Biologics
- 10 May 2010 Discontinued - Preclinical for Solid tumours in Italy (Parenteral)
- 29 Jun 2009 Preclinical trials in Solid tumours in Italy (Parenteral)